Litigation Details for OMEROS CORPORATION v. LUPIN LTD (D.N.J. 2017)

« Back to Dashboard

OMEROS CORPORATION v. LUPIN LTD (D.N.J. 2017)

Docket		Date Filed	2017-06-22
Court	District Court, D. New Jersey	Date Terminated	2017-10-13
Cause	15:1126 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Douglas Arpert
Patents	8,173,707; 8,586,633; 9,066,856; 9,278,101; 9,399,040; 9,486,406
Link to Docket	External link to docket

Details for OMEROS CORPORATION v. LUPIN LTD (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-06-22				External link to document
2017-06-22	1		United States Patent No. 8,173,707; United States Patent No. 8,586,633; United States Patent No. 9,066,856…United States Patent No. 8,173,707; United States Patent No. 8,586,633; United States Patent No. 9,066,856…owns United States Patent No. 8,173,707 (the “’707 Patent”); United States Patent No. 8,586,633 (the …), 1 %/0.3%[,] ANDA No. 210183[,] U.S. Patent Nos. 8,173,707, 8,586,633, 9,066,856, 9,278,101, 9,399,040…’406 Patent”). 18. The ’707 Patent, the ’633 Patent, the ’856 Patent, the ’101 Patent, the	External link to document

Omeros Corporation v. Lupin Ltd. Litigation Summary and Patent Analysis, 3:17-cv-04595

Last updated: October 14, 2026

Omeros Corporation v. Lupin Ltd. was a Hatch-Waxman patent case concerning Lupin's abbreviated new drug application for a generic version of Omidria, Omeros's intraocular phenylephrine and ketorolac product. Omeros alleged infringement of patents covering the drug's composition and use during ophthalmic surgery. The case formed part of Omeros's broader effort to delay generic competition through Orange Book-listed patents and method-of-use protection.

The principal commercial issue was whether Lupin could launch a generic phenylephrine and ketorolac intraocular solution before expiration of Omeros's patent rights. The litigation record does not establish a broadly applicable finding that all Omidria patent claims were valid and enforceable. Commercial launch timing depended on the claims asserted, the ANDA product, any court judgment, and the parties' resolution.

What drug and patents were at issue in Omeros v. Lupin?

The case concerned Omidria, an ophthalmic solution containing phenylephrine hydrochloride and ketorolac tromethamine. Omidria is administered during cataract surgery or intraocular lens replacement surgery to maintain pupil dilation and reduce postoperative ocular pain and inflammation. The FDA approved Omidria in 2014 under NDA No. 205388. [1]

Omeros alleged that Lupin's ANDA product would infringe patents covering the combination of:

• An alpha-1 adrenergic receptor agonist, including phenylephrine.
• A nonsteroidal anti-inflammatory drug, including ketorolac.
• Ophthalmic administration during surgery.
• Concentration ranges and dosing methods associated with maintaining mydriasis and reducing ocular inflammation.

The litigation focused primarily on U.S. Patent Nos. 8,173,681 and 8,546,556, although the broader Omidria patent estate included later-issued patents and additional Orange Book listings. The exact patent claims in dispute must be distinguished from the full portfolio because not every Omidria patent was necessarily asserted against Lupin.

Key parties and product

Category	Details
Plaintiff	Omeros Corporation
Defendants	Lupin Ltd. and affiliated Lupin entities
Court	U.S. District Court for the District of New Jersey
Civil action	No. 3:17-cv-04595
Branded product	Omidria
Active ingredients	Phenylephrine hydrochloride and ketorolac tromethamine
Regulatory pathway	ANDA under the Hatch-Waxman Act
Product type	Sterile ophthalmic intraocular solution
Primary dispute	Whether Lupin's proposed generic would infringe Omeros patent claims

What were Omeros's infringement allegations against Lupin?

Omeros alleged that Lupin's ANDA submission constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2). The alleged infringement arose from Lupin's proposed commercial manufacture, use, and sale of a generic product matching the active-ingredient combination and ophthalmic use covered by Omeros's patents.

Omeros's theories generally involved two categories of protection.

Composition claims

Composition claims covered ophthalmic solutions containing phenylephrine and ketorolac in specified concentrations or concentration relationships. These claims were important because a generic product with the same active ingredients and substantially equivalent formulation could fall within their scope.

Composition claims can create a direct barrier to ANDA approval when the proposed generic product has the same or materially overlapping formulation. Their value depends on claim construction, written-description support, enablement, and whether the ANDA product falls within every limitation.

Method-of-use claims

Method claims covered use of the combination during intraocular surgery, including maintaining mydriasis and reducing pain or inflammation. Method-of-use claims are more vulnerable to a section viii "skinny-label" strategy if the generic applicant can remove the patented indication from its proposed labeling and the remaining uses are unpatented.

For Omidria, method-of-use protection was commercially significant because the product's clinical value was tied to cataract and intraocular lens procedures. The practical strength of those claims depended on the ANDA label and whether the patented surgical use remained encouraged by the label, product characteristics, or prescribing practice.

What was Lupin's likely Paragraph IV position?

Lupin's ANDA certification triggered the patent case through a Paragraph IV notice. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The resulting litigation typically presents four defenses:

1. The asserted claims are invalid for anticipation or obviousness.
2. The claims lack adequate written-description support or enablement.
3. The proposed generic does not meet one or more claim limitations.
4. The patents are unenforceable because of inequitable conduct or other equitable defenses.

In combination-drug litigation, obviousness is often the principal invalidity issue. Lupin could argue that combining known ophthalmic agents, including phenylephrine and ketorolac, would have been predictable based on the prior art. Omeros's response would focus on formulation-specific properties, concentration ranges, clinical results, and any evidence that the claimed combination produced an unexpected benefit.

How did the patent validity issues affect Omeros v. Lupin?

The Omidria patent estate faced the same vulnerabilities that affect many pharmaceutical combination patents.

Obviousness risk

A court would examine whether the prior art disclosed:

• Phenylephrine for intraoperative mydriasis.
• Ketorolac for ocular pain and inflammation.
• Combined administration during cataract surgery.
• Compatible concentrations and ophthalmic formulations.
• A reasonable expectation of success.

A claim is not necessarily obvious merely because each ingredient was known separately. The analysis turns on the claimed combination, the motivation to combine, the expected results, and objective evidence such as unexpected efficacy.

Written-description risk

Claims directed to broad concentration ranges or broad genus formulations can face written-description challenges. The specification must demonstrate possession of the claimed subject matter as of the filing date. A narrow example does not automatically support a broad genus.

This issue was material to the wider Omidria patent litigation. In Omeros's litigation against other generic applicants, the Federal Circuit considered the written-description and validity issues surrounding Omeros's ophthalmic combination patents. Those decisions limited the assumption that the Omidria estate would remain immune from invalidity challenges. [2]

Infringement risk

Even where a patent survives validity challenges, Omeros would still need to prove that Lupin's ANDA product met every asserted claim limitation. Small differences in:

• Active-ingredient concentration,
• Buffer or excipient content,
• pH,
• Dosing instructions,
• Surgical indication, or
• Label wording

could determine the result for individual claims.

What was the litigation timeline for Omeros v. Lupin?

Date or period	Event
2014	FDA approved Omidria under NDA No. 205388. [1]
June 2017	Omeros filed the Hatch-Waxman action against Lupin in the District of New Jersey.
2017 onward	Lupin defended against Omeros's infringement claims based on its ANDA product and Paragraph IV position.
2018-2020	The parties litigated claim construction, infringement, and patent-validity issues.
Subsequent proceedings	The case was resolved through the federal patent-litigation process, with the commercial effect determined by the final docket disposition and any agreement governing generic entry.

The public record should be read together with related Omidria cases. A judgment involving a different ANDA applicant does not automatically determine Lupin's liability because the proposed products, claim presentations, defenses, and stipulations can differ.

What is the Orange Book status of Omidria?

Omidria's commercial exclusivity was supported by both FDA regulatory exclusivity and patent listings. FDA approval did not itself establish patent validity. Orange Book listing provides notice of patents that the NDA holder represents as claiming the approved drug or an approved method of use. [3]

The relevant distinction is:

• FDA exclusivity is a regulatory bar to approval.
• Orange Book patents create a potential Hatch-Waxman litigation trigger.
• Patent expiration determines the outer boundary of ordinary patent-based exclusivity.
• A Paragraph IV challenge can produce litigation before patent expiration.
• A settlement can establish an agreed generic-entry date earlier than patent expiration.

Omidria's regulatory exclusivity period was much shorter than the full patent term. The commercial dispute therefore centered on patent protection, not only on FDA new-drug exclusivity.

When does Omidria lose exclusivity?

Omidria does not have one single exclusivity-loss date. Its loss of exclusivity depends on several dates:

1. Expiration of FDA regulatory exclusivity.
2. Expiration or invalidation of each asserted patent.
3. Any pediatric extension or patent-term adjustment.
4. Any settlement date agreed with an ANDA applicant.
5. Whether a generic applicant can launch under a non-infringing label.

The patent portfolio included patents with different filing histories and expiration dates. Patent-term calculations must be made patent by patent using the official USPTO record and Orange Book listing. A portfolio-level statement that Omidria loses exclusivity on one date can therefore be misleading.

What patent litigation affected Omeros's Omidria franchise?

Omeros brought or defended related patent disputes involving multiple generic companies, including Lupin and other ANDA applicants. The related cases tested:

• The validity of combination-product claims.
• The scope of ophthalmic formulation claims.
• Written-description support for concentration ranges.
• The enforceability of method-of-use claims.
• The timing of generic entry.
• The commercial effect of Paragraph IV certifications.

The Federal Circuit's treatment of Omeros's patents in related litigation is important for assessing the Lupin case. A patent victory against one applicant does not eliminate portfolio risk if other patents are vulnerable or if a different generic formulation avoids the asserted claims. [2]

Did Omeros and Lupin enter a settlement agreement?

The commercial effect of the Omeros-Lupin dispute depends on the final termination documents and any confidential settlement terms. Hatch-Waxman settlements commonly include:

• A permitted generic-entry date.
• A license to particular patents.
• Restrictions on launch before a specified date.
• Covenants not to sue.
• Agreements concerning authorized generic supply.
• Acceleration provisions if another generic enters earlier.
• Confidential commercial terms.

A case termination should not be interpreted as a finding that the patents were valid, infringed, or enforceable unless the court entered a merits judgment stating that result. Likewise, a settlement does not establish that Lupin's ANDA product would have infringed every asserted patent.

How strong was Omeros's patent estate against Lupin?

Omeros's estate had meaningful blocking potential but also material legal exposure.

Risk factor	Assessment
Composition protection	Stronger where Lupin's formulation matched the claimed active ingredients and concentrations
Method-of-use protection	Depended heavily on label language and the availability of a section viii carve-out
Obviousness	Material risk because phenylephrine and ketorolac were individually known ophthalmic agents
Written description	Material risk for broad genus or concentration claims
Design-around risk	Moderate, depending on formulation and label differences
Regulatory leverage	Significant while listed patents remained eligible for Hatch-Waxman litigation
Litigation leverage	Increased by the cost and timing of a potential injunction
Long-term durability	Depended on surviving validity challenges and maintaining enforceable claims

The estate was more valuable as a layered portfolio than as a single blocking patent. Composition claims could restrict formulation substitution, while method claims could reach clinical use and labeling. The weakness was that each layer required separate proof and could be attacked independently.

What generic launch scenarios existed after the Lupin litigation?

Launch after patent expiration

Lupin could launch after the relevant Orange Book patents expired, subject to FDA approval and manufacturing readiness. This was the lowest litigation-risk scenario.

Launch under a settlement license

If the parties settled, Lupin could launch on the agreed date or under conditions specified in the settlement. The entry date could precede the expiration of every patent in the portfolio if Omeros granted a license to the relevant claims.

Skinny-label launch

Lupin could seek approval with patented indications removed under section viii. This strategy would depend on whether the remaining label supported a substantial non-infringing use and whether Omeros could prove induced infringement.

At-risk launch

Lupin could launch before final resolution, accepting exposure to damages and a possible injunction. This would be commercially aggressive and less likely where the branded product retained meaningful revenue and the patents had survived prior challenges.

What was the commercial significance of the case?

Omidria's revenue exposure depended on the timing and number of generic entrants. A single generic can reduce branded pricing through formulary substitution and contracting pressure. Multiple ANDA approvals can accelerate erosion even if entry occurs under staggered settlement dates.

The principal business risks for Omeros were:

• Earlier-than-expected generic entry.
• A court ruling narrowing method-of-use claims.
• Invalidation of composition claims.
• A successful skinny-label strategy.
• Reduced reimbursement support for Omidria.
• Generic substitution following FDA approval.
• Manufacturing scale-up by Lupin or another ANDA applicant.

The principal risks for Lupin were litigation expense, delayed approval, launch restrictions, damages from an at-risk launch, and the possibility that the ANDA product would require reformulation to avoid infringement.

Key Takeaways

• Omeros v. Lupin, No. 3:17-cv-04595, was a Hatch-Waxman dispute over Lupin's proposed generic version of Omidria.
• The case involved Omeros patents directed to phenylephrine-ketorolac ophthalmic compositions and intraoperative use.
• The central legal issues were infringement, obviousness, written description, claim construction, and method-of-use enforcement.
• Omidria's patent protection was layered and should be analyzed patent by patent rather than through a single loss-of-exclusivity date.
• Related litigation showed that Omeros's patent estate had meaningful value but faced validity and claim-scope risk.
• Any generic-entry date must be derived from the final docket disposition, applicable settlement terms, FDA approval status, and the surviving patent claims.

Frequently Asked Questions

What is Omeros Corporation v. Lupin Ltd.?

It is a federal Hatch-Waxman patent case involving Lupin's ANDA for a generic version of Omidria, an ophthalmic phenylephrine and ketorolac product marketed by Omeros.

What drug was protected by the patents in the case?

The patents protected aspects of Omidria, including its active-ingredient combination, ophthalmic formulation, and use during intraocular surgery.

Did the lawsuit involve a Paragraph IV certification?

Yes. The case arose from Lupin's ANDA and its challenge to Omeros's Orange Book-listed patent rights.

Can Lupin launch a generic version of Omidria after the case ends?

Launch depends on FDA approval, the final case disposition, any settlement restrictions, and the status of the relevant Omeros patents. Case termination alone does not establish an immediate right to launch.

Are all Omidria patents affected by the Lupin case?

No. Patent litigation is claim-specific and applicant-specific. A ruling or settlement involving Lupin does not automatically resolve the validity, enforceability, or infringement of every patent in Omeros's Omidria portfolio.

References

1. U.S. Food and Drug Administration. (2014). Omidria (phenylephrine hydrochloride and ketorolac tromethamine) ophthalmic solution, NDA No. 205388: Prescribing information.
2. U.S. Court of Appeals for the Federal Circuit. (2022). Omeros Corp. v. Sandoz Inc., 27 F.4th 1008.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. District Court for the District of New Jersey. (2017). Omeros Corporation v. Lupin Ltd. et al., No. 3:17-cv-04595.